Arca

Pharma markets this week

Sep 14 to Sep 20, 2026

2 funding rounds, 2 PDUFA dates, 5 officer changes.

Funding rounds of $5 million or more, and IPOs 2

Funding rounds

PDUFA dates companies have disclosed 2

PDUFA calendar

Ultragenyx Pharmaceutical Inc.

FDA goal date for UX111 (rebisufligene etisparvovec) (BLA), for Sanfilippo syndrome type A (MPS IIIA)

2026-09-19 · Disclosed by Ultragenyx Pharmaceutical Inc.

Source

Nuvalent, Inc.

FDA goal date for zidesamtinib (NDA), for TKI pre-treated locally advanced or metastatic ROS1-positive non-small cell lung cancer

2026-09-18 · Disclosed by Nuvalent, Inc.

Source

Officer and director changes 5

Glucotrack, Inc.

Change in directors or officers

2026-09-18 · Form 8-K, Item 5.02. The filing does not say who joined or left.

Source